Ocular Therapeutix Inc [OCUL] stock prices are up 1.04% to $7.75 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The OCUL shares have gain 4.17% over the last week, with a monthly amount glided 11.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ocular Therapeutix Inc [NASDAQ: OCUL] stock has seen the most recent analyst activity on March 18, 2025, when RBC Capital Mkts initiated its Outperform rating and assigned the stock a price target of $17. Previously, Needham started tracking the stock with Buy rating on March 11, 2025, and set its price target to $15. On October 16, 2024, Scotiabank initiated with a Sector Outperform rating. TD Cowen upgraded its rating to a Buy and increased its price target to $11 on June 20, 2024. BofA Securities started tracking with a Buy rating for this stock on February 09, 2024, and assigned it a price target of $15. In a note dated April 21, 2023, Robert W. Baird initiated an Outperform rating and provided a target price of $18 on this stock.
The stock price of Ocular Therapeutix Inc [OCUL] has been fluctuating between $4.06 and $11.77 over the past year. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Ocular Therapeutix Inc [NASDAQ: OCUL] shares were valued at $7.75 at the most recent close of the market. An investor can expect a potential return of 145.16% based on the average OCUL price forecast.
Analyzing the OCUL fundamentals
The Ocular Therapeutix Inc [NASDAQ:OCUL] reported sales of 63.72M for trailing twelve months, representing a surge of 15.40%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -2.7%, Pretax Profit Margin comes in at -3.04%, and Net Profit Margin reading is -3.04%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -0.53 and Total Capital is -0.41. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.59 points at the first support level, and at 7.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.98, and for the 2nd resistance point, it is at 8.20.
Ratios To Look Out For
It’s worth pointing out that Ocular Therapeutix Inc [NASDAQ:OCUL]’s Current Ratio is 10.66. As well, the Quick Ratio is 10.59, while the Cash Ratio is 9.48. Considering the valuation of this stock, the price to sales ratio is 19.34, the price to book ratio is 3.88.
Transactions by insiders
Recent insider trading involved Dugel Pravin,, that happened on Feb 24 ’25 when 21475.0 shares were sold. Chief Scientific Officer, Heier Jeffrey S. completed a deal on Feb 24 ’25 to sell 3061.0 shares. Meanwhile, Chief Development Officer Kaiser Peter sold 3009.0 shares on Feb 24 ’25.
